相似文献
1
[Perioperative application of recombinant human coagulation factor Ⅶa combined with prothrombin complex in two hemophilia A patients with high titer inhibitor].
Zhonghua Xue Ye Xue Za Zhi. 2020 Sep 14;41(9):773-775. doi: 10.3760/cma.j.issn.0253-2727.2020.09.013.
2
Treatment of an acquired factor VIII inhibitor with sequential recombinant factor VIIa and FEIBA.
Haemophilia. 2009 Jan;15(1):383-5. doi: 10.1111/j.1365-2516.2008.01869.x. Epub 2008 Aug 27.
3
Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding.
Haemophilia. 2008 Mar;14(2):390-1. doi: 10.1111/j.1365-2516.2007.01635.x. Epub 2008 Jan 10.
4
Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
Cochrane Database Syst Rev. 2015 Dec 16;2015(12):CD004449. doi: 10.1002/14651858.CD004449.pub4.
5
Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.
Thromb Res. 1999 Aug 15;95(4 Suppl 1):S31-8. doi: 10.1016/s0049-3848(99)00082-1.
6
Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient.
Thromb Haemost. 2002 May;87(5):925-6.
7
Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
Am J Hematol. 2004 Dec;77(4):346-50. doi: 10.1002/ajh.20204.
8
Successful use of recombinant factor VIIa for emergency fasciotomy in a patient with hemophilia A and high-titer inhibitor unresponsive to factor VIII inhibitor bypassing activity.
Am J Hematol. 2005 May;79(1):58-60. doi: 10.1002/ajh.20314.
9
The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
Vox Sang. 1999;77 Suppl 1:38-41. doi: 10.1159/000056714.
10
Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry.
J Thromb Haemost. 2015 Jul;13(7):1279-84. doi: 10.1111/jth.12987. Epub 2015 May 29.
引用本文的文献
1
Sequential combined bypassing therapy in haemophilia patients with high titer inhibitors: surgical experience.
Ann Hematol. 2025 Mar;104(3):1949-1960. doi: 10.1007/s00277-025-06265-6. Epub 2025 Feb 26.
本文引用的文献
1
European principles of inhibitor management in patients with haemophilia.
Orphanet J Rare Dis. 2018 Apr 27;13(1):66. doi: 10.1186/s13023-018-0800-z.
2
Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B--a systematic literature review.
Eur J Haematol Suppl. 2014 Aug;76:26-38. doi: 10.1111/ejh.12372.
3
Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen.
Haemophilia. 2014 Jul;20(4):587-92. doi: 10.1111/hae.12365. Epub 2014 Feb 11.
4
Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.
Br J Haematol. 2011 Oct;155(2):256-62. doi: 10.1111/j.1365-2141.2011.08854.x. Epub 2011 Sep 7.
5
Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.
Haemophilia. 2011 Jul;17(4):630-5. doi: 10.1111/j.1365-2516.2010.02467.x. Epub 2011 Feb 15.
6
Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.
Haemophilia. 2009 Sep;15(5):1083-9. doi: 10.1111/j.1365-2516.2009.02038.x. Epub 2009 Apr 27.
7
Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding.
Haemophilia. 2008 Mar;14(2):390-1. doi: 10.1111/j.1365-2516.2007.01635.x. Epub 2008 Jan 10.
Zotero 插件